One year af­ter wrap­ping PhI, Bio­gen drops ALS drug it bought from Karyopharm for $10M cash

A lot has changed in the four years since Bio­gen paid $10 mil­lion cash to buy Karyopharm’s neu­ro-di­rect­ed XPO1 in­hibitor.

Karyopharm steered its oth­er XPO1 drug, se­linex­or, to an FDA ap­proval. Bio­gen, hav­ing re­named KPT-350 to BI­IB100, chose to po­si­tion the can­di­date as a po­ten­tial treat­ment for amy­otroph­ic lat­er­al scle­ro­sis (out of a num­ber of neu­rode­gen­er­a­tive con­di­tions) and com­plet­ed a Phase I tri­al — even as the Alzheimer’s drug that be­came Aduhelm hawked the spot­light.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER